THIS WARRANT AND THE COMMON SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THIS WARRANT AND THE COMMON SHARES ISSUABLE UPON EXERCISE OF THIS...EconoShare, Inc. • September 28th, 2006
REGISTRATION RIGHTS AGREEMENTSubscription Agreement • September 28th, 2006 • EconoShare, Inc. • New York
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • August 4th, 2020 • Innovation Pharmaceuticals Inc. • Pharmaceutical preparations • Nevada
This COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), is dated as of July 31, 2020 by and between INNOVATION PHARMACEUTICALS INC., a Nevada corporation (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (the “Buyer”).Capitalized terms used herein and not otherwise defined herein are defined in Section 10 hereof.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 4th, 2020 • Innovation Pharmaceuticals Inc. • Pharmaceutical preparations • Nevada
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July 31, 2020, by and between INNOVATION PHARMACEUTICALS INC., a Nevada corporation (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Buyer”).Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Common Stock Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 10th, 2020 • Innovation Pharmaceuticals Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of December 9, 2020, between Innovation Pharmaceuticals Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). The Company agrees that in this case, there will be only one Purchaser.
FORM OF WARRANT TO PURCHASE COMMON STOCKInnovation Pharmaceuticals Inc. • June 29th, 2018 • Pharmaceutical preparations • Nevada
Innovation Pharmaceuticals Inc., a Nevada corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, _____, or its permitted registered assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company up to a total of _____ shares of Class A common stock, $0.0001 par value per share (the “Common Stock”), of the Company (each such share, a “Warrant Share” and all such shares, the “Warrant Shares”) at an exercise price per share equal to $0.01 per share (as adjusted from time to time as provided in Section 9 herein, the “Exercise Price”), upon surrender of this warrant to purchase Common Stock (including any warrants to purchase Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”) at any time and from time to time on or after the date hereof (the “Original Issue Date”) and through and including 5:30 P.M., New York City time, on the
COMPOUND ASSIGNMENT AGREEMENTCompound Assignment Agreement • December 12th, 2007 • EconoShare, Inc. • Services-business services, nec • New York
In consideration of the mutual promises set forth in this Compound Assignment Agreement (the "Agreement"), Dr. Krishna Menon, residing at 21 Rocky Road, Reading MA 01867 (the "Inventor") and Cellceutix Corporation, a Delaware corporation with an office at 760 Main St., Willmington Ma 01887 ("Cellceutix") agree as follows:
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 10th, 2012 • Cellceutix CORP • Pharmaceutical preparations • Nevada
REGISTRATION RIGHTS AGREEMENT(this “Agreement”), dated as of December 6, 2012, by and between CELLCEUTIX CORPORATION, a Nevada corporation (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Common Stock Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
EMPLOYMENT AGREEMENT BETWEEN CELLCEUTIX CORPORATION AND LEO EHRLICHEmployment Agreement • February 22nd, 2011 • Cellceutix CORP • Pharmaceutical preparations • New York
Form of Restricted Stock Award Agreement for Non-employee DirectorsRestricted Stock Award Agreement • July 1st, 2016 • Cellceutix CORP • Pharmaceutical preparations • Nevada
This Restricted Stock Award Agreement (this "Agreement") is made and entered into as of ____________ (the "Grant Date") by and between Cellceutix Corporation, a Nevada corporation (the "Company") and ______________ (the "Director").
AMENDED AND RESTATED SECURITY AGREEMENTAmended and Restated Security Agreement • April 1st, 2011 • Cellceutix CORP • Pharmaceutical preparations • New York
AMENDED AND RESTATED SECURITY AGREEMENT (this “Agreement”), dated as of January 1, 2011, by and between Cellceutix Corporation, a Nevada corporation (“Company”), and Cellceutix Pharma, Inc., a Delaware corporation (“Cellceutix Delaware” and, together with the Company, the “Debtors”), and the secured party signatory hereto (the “Secured Party”).
SERIES 1/2 PREFERRED STOCK PURCHASE WARRANT INNOVATION PHARMACEUTICALS INC.Innovation Pharmaceuticals Inc. • December 10th, 2020 • Pharmaceutical preparations
THIS SERIES 1/2 PREFERRED STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 6:00 p.m. (New York City time) on _______1 (provided that, if such date is not a Trading Day, then such date shall be the immediately following Trading Day) (the “Termination Date”) but not thereafter, to subscribe for and purchase from Innovation Pharmaceuticals Inc., a Nevada corporation (the “Company”), up to ______2shares (as subject to adjustment hereunder, the “Warrant Shares”) of Series B-2 5% Convertible Preferred Stock of the Company (the “Preferred Stock”); provided, however, that, in the event of an Authorized Share Failure (as defined in the Purchase Agreement) or a Registration Statement Availability Failure, for each day of an Authorized Share Failure and for
AMENDED AND RESTATED GUARANTYAmended and Restated Guaranty • April 1st, 2011 • Cellceutix CORP • Pharmaceutical preparations • New York
AMENDED AND RESTATED GUARANTY (this "Guaranty"), dated as of January 1, 2011, by Cellceutix Pharma, Inc., a Delaware corporation with an address of 100 Cummings Center, Suite 151-B, Beverly, MA 01915 (the "Guarantor"), in favor of Dahlia Kalter Nordlicht & Mark A. Nordlicht (the "Secured Party").
SECURITY AGREEMENTSecurity Agreement • May 15th, 2008 • EconoShare, Inc. • Pharmaceutical preparations • New York
SECURITY AGREEMENT (this “Agreement”), dated as of May 7, 2008, by and between Cellceutix Corporation, a Nevada corporation (“Company”), and Cellceutix Pharma, Inc., a Delaware corporation (“Cellceutix Delaware” and, together with the Company, the “Debtors”), and the secured party signatory hereto (the “Secured Party”).
PATENT LICENSE AGREEMENT BETWEEN POLYMEDIX, INC. AND THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA PATENT LICENSE AGREEMENTPatent License Agreement • September 30th, 2013 • Cellceutix CORP • Pharmaceutical preparations • Pennsylvania
This Patent License Agreement (this “Agreement”) is made on January 3, 2003 (the “Effective Date”), by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation, with offices located at 3160 Chestnut Street, Suite 200, Philadelphia, Pennsylvania 19104-3147 (“Penn”), and Polymedix, Inc., a Delaware corporation (“Licensee”), with its principal offices at 5 Radnor Corporate Center, 100 Matsonford Road, Suite 520, Radnor, PA 19087.
CELLCEUTIX CORPORATION Amended and Restated Subscription AgreementSubscription Agreement • January 22nd, 2013 • Cellceutix CORP • Pharmaceutical preparations • Nevada
THIS AMENDED AND RESTATED SUBSCRIPTION AGREEMENT (the "Agreement") is entered into as of the 26th day of January 2012 , by and among Cellceutix Corporation, a Nevada corporation ("the Company") and Huang Min Chung., the holder of 2,500,000 Company's Common Stock, and Common Stock Purchase Warrants, Series AH101, AH102, AH-103.
MATERIAL TRANSFER AGREEMENTMaterial Transfer Agreement • May 12th, 2014 • Cellceutix CORP • Pharmaceutical preparations • Massachusetts
This Material Transfer Agreement (“MTA”) has been adopted for use by Cellceutix Corporation, 100 Cummings Center, Suite 151-B, Beverly, MA 01915 (“Cellceutix”) in all transfers of research material (“Research Material”) whether Cellceutix is identified below as its Provider or Recipient.
GUARANTYGuaranty • May 15th, 2008 • EconoShare, Inc. • Pharmaceutical preparations • New York
GUARANTY (the “Guaranty”), dated as of May 7 , 2008, by Cellceutix Pharma, Inc., a Delaware corporation with an address of 187 Ballard St., Suite A225, Wilmington, MA 01887 (the “Guarantor”), in favor of Putnam Partners, White Star LLC Dahlia Nordlicht (the “Secured Parties”).
AMENDED AND RESTATED GUARANTYSecurity Agreement • April 1st, 2011 • Cellceutix CORP • Pharmaceutical preparations • New York
AMENDED AND RESTATED GUARANTY (this "Guaranty"), dated as of January 1, 2011, by Cellceutix Pharma, Inc., a Delaware corporation with an address of 100 Cummings Center, Suite 151-B, Beverly, MA 01915 (the "Guarantor"), in favor of White Star, LLC (the "Secured Party").
SOFTWARE LICENSE AGREEMENT BETWEEN POLYMEDIX, INC. AND THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA SOFTWARE LICENSE AGREEMENTSoftware License Agreement • September 30th, 2013 • Cellceutix CORP • Pharmaceutical preparations • Pennsylvania
This Software License Agreement (this “Agreement”) is made on May 30, 2003 (the “Effective Date”), by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation, with offices located at 3160 Chestnut Street, Suite 200, Philadelphia, Pennsylvania 19104-3147 (“Penn”), and Polymedix, Inc., a Delaware corporation (“Licensee”), with its principal offices at 5 Radnor Corporate Center, 100 Matsonford Road, Suite 520, Radnor, PA 19087.
PROJECT AGREEMENT AND LETTER OF AUTHORIZATIONProject Agreement • April 1st, 2011 • Cellceutix CORP • Pharmaceutical preparations
EMPLOYMENT AGREEMENTEmployment Agreement • December 12th, 2007 • EconoShare, Inc. • Services-business services, nec • New York
This Agreement (the “Agreement”) dated as of December 7, 2007 is made by and between ECONOSHARE, INC., a publicly-owned Nevada corporation (the “Company”) and GEORGE EVANS (the “Executive”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 9th, 2018 • Innovation Pharmaceuticals Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of October 5, 2018, between Innovation Pharmaceuticals Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
Form of Restricted Stock Award Agreement for EmployeesForm of Restricted Stock Award Agreement for Employees • July 1st, 2016 • Cellceutix CORP • Pharmaceutical preparations • Nevada
This Restricted Stock Award Agreement (this "Agreement") is made and entered into as of ___________ (the "Grant Date") by and between Cellceutix Corporation, a Nevada corporation (the "Company") and ______________ (the "Grantee").
Agreement Cellceutix Corporation -and- James M. DeAngelis ("Consultant")Agreement • May 21st, 2009 • Cellceutix CORP • Pharmaceutical preparations • Massachusetts
This Agreement (the “Agreement”) is entered into as of May 6, 2009 by and between Cellceutix Corporation (hereinafter “Cellceutix”) a Nevada corporation with a principal place of business at 100 Cummings Park, Suite 151-B, Beverly Massachusetts 01915 and James DeAngelis (hereinafter, “Consultant”), an individual residing at 541 Bellvue Avenue, Unit #1, Newport, RI, 02840 (collectively, the “parties”).
FORM OF WARRANT AMENDMENT AGREEMENTWarrant Amendment Agreement • December 26th, 2019 • Innovation Pharmaceuticals Inc. • Pharmaceutical preparations
This Warrant Amendment Agreement (this “Agreement”), dated as of December 26, 2019, is made pursuant to that certain Securities Purchase Agreement, dated as of October 5, 2018 (the “Purchase Agreement”), as amended, by and between Innovation Pharmaceuticals Inc. (the “Company”) and the purchasers signatory hereto (the “Purchasers”) for the purchase of shares of the Company’s Series B 5% Convertible Preferred Stock (the “Series B Preferred”) and Series 2 Warrants, Series 3 Warrants and Series 4 Warrants to purchase shares of Series B Preferred (“Warrants”). Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement, as amended.
ContractAgreement and Plan of Share Exchange • December 12th, 2007 • EconoShare, Inc. • Services-business services, nec • New York
THIS AGREEMENT AND PLAN OF SHARE EXCHANGE (hereinafter referred to as the “Agreement”), is entered into as of this 6th day of December, 2007, by and among, ECONOSHARE, INC., a publicly-owned Nevada corporation (“ECSR”), CELLCEUTIX PHARMA, INC., a Delaware corporation (“CPI”), and the shareholders of CPI on the signature page hereof (the “CPI Shareholders”). (ECSR, CPI, and the CPI Shareholders are sometimes hereinafter collectively referred to as the “Parties” and individually as a “Party.”)
AMENDED AND RESTATED GUARANTYGuaranty • February 22nd, 2011 • Cellceutix CORP • Pharmaceutical preparations • New York
AMENDED AND RESTATED GUARANTY (this "Guaranty"), dated as of January 1, 2011, by Cellceutix Pharma, Inc., a Delaware corporation with an address of 100 Cummings Center, Suite 151-B, Beverly, MA 01915 (the "Guarantor"), in favor of White Star, LLC (the "Secured Party").
COMPOUND ASSIGNMENT AGREEMENTCompound Assignment Agreement • December 12th, 2007 • EconoShare, Inc. • Services-business services, nec • New York
In consideration of the mutual promises set forth in this Compound Assignment Agreement (the "Agreement"), Geetha Kamburath, , residing at Skanda Kripa, Payalore, Kerala, India ) (the "Inventor") and Cellceutix Corporation, a Delaware corporation with an office at 760 Main St., Willmington Ma 01887 ("Cellceutix") agree as follows:
FIRST AMENDMENT TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • September 9th, 2013 • Cellceutix CORP • Pharmaceutical preparations
THIS FIRST AMENDMENT TO ASSET PURCHASE AGREEMENT (this “Amendment”), dated as of August 30, 2013, is made and entered into by and between Cellceutix Corporation (the “Purchaser”) and Jeoffrey L. Burtch, as chapter 7 trustee (the “Seller” and, together with the Purchaser, the “Parties”) for the bankruptcy estates of PolyMedix, Inc. and PolyMedix Pharmaceuticals, Inc.
AMENDMENT TO MENON- CELLCEUTIX AGREEMENT WITHOUT CHANGING THE TOTAL AMOUNT OF ROYALTIES PAYABLE UNDER THE TERMS OF THE PRIOR AGREEMENTPrior Agreement • September 2nd, 2014 • Cellceutix CORP • Pharmaceutical preparations • Massachusetts
This Amendment, effective on signature of the last party to sign (“Effective Date”), between Dr. Krishna Menon, (hereinafter “Menon”) and Cellceutix Corporation, a Nevada corporation located at 100 Cummings Center, Suite 151, Beverly MA 01915 USA (hereinafter “Cellceutix”), amends a prior agreement between these parties dated October 17, 2007 (“Prior Agreement” Attachment A hereto), by which Menon assigned to Cellceutix all right, title and interest to a Compound (as defined therein) and patents thereon in consideration for a percentage of Net Sales of the Compound, also known as Kevetrin.
Form of Non-qualified Stock Option Agreement for EmployeesQualified Stock Option Agreement for Employees • July 1st, 2016 • Cellceutix CORP • Pharmaceutical preparations • Nevada
This Stock Option Agreement (this "Agreement") is made and entered into as of ___________ by and between Cellceutix Corporation, a Nevada corporation (the "Company") and _________________ (the "Participant").
Mutual Termination AgreementMutual Termination Agreement • January 8th, 2013 • Cellceutix CORP • Pharmaceutical preparations
This mutual termination agreement is made and entered into this 8thday of January, 2013, by and between Cellceutix Corporation and Hyman and Ethel Schwartz, (“Schwartz”) Series A Convertible Preferred Subscriber.
EMPLOYMENT AGREEMENTEmployment Agreement • October 24th, 2014 • Cellceutix CORP • Pharmaceutical preparations • Massachusetts
THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into effective as of the 27th day of October, 2014 (the “Effective Date”), by and between Cellceutix Corporation, a Nevada corporation (the “Company”), and Dr. William James Alexander, an individual (the “Executive”).
SETTLEMENT AGREEMENT AND RELEASESettlement Agreement and Release • February 22nd, 2011 • Cellceutix CORP • Pharmaceutical preparations • New York
This Settlement Agreement and Release (“Agreement”) is entered into as of January __, 2011, by and between George W. Evans (“Employee”), George W. Evans, III, Timothy P. Evans and Cellceutix Corporation, a Nevada corporation (the “Company”, and together with Employee, George W. Evans, III and Timothy P. Evans, are collectively referred to as the “Parties” and each individually as a ‘Party’”).
